NARS2 and cutaneous melanoma: Xie et al. demonstrated that the enhanced expression of four lactate risk-related genes, SLC25A3, HPDL, NDUFA13, and NARS2, was correlated with poor prognosis in patients with skin cutaneous melanoma (SKCM), while patients with risk-related gene expression may benefit more from immune checkpoint inhibitor (ICI) therapy (Xie et al., 2022).